Cargando…
The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
Mature overall survival (OS) data are often unavailable at the time of regulatory and reimbursement decisions for a new cancer treatment. For patients with early-stage cancers treated with potentially curative treatments, demonstrating an OS benefit may take years and may be confounded by subsequent...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592394/ https://www.ncbi.nlm.nih.gov/pubmed/34795526 http://dx.doi.org/10.2147/CMAR.S328058 |